SKYEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases...

Stats
本日の出来高	31 336.00
平均出来高	44 212.00
時価総額	12.63B
EPS	$0 ( 2024-03-31 )
次の収益日	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.150
ATR14	$0.0280 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	5am Partners Vii, Llc	Buy	450 000	Common Stock
2024-03-13	Schwab Andrew J.	Buy	450 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	100 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	35 000	Stock Option (Right to Buy)
2024-02-29	Charych Deborah H.	Buy	35 000	Stock Option (Right to Buy)

INSIDER POWER
98.76
Last 83 transactions
Buy: 1 749 377 489 \| Sell: 16 641 486

ボリューム相関

長: -0.10 (neutral)

短: -0.34 (neutral)

Signal:(50.079) Neutral

Skye Bioscience, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Skye Bioscience, Inc. 相関 - 通貨/商品

-0.18
( neutral )

-0.06
( neutral )

0.00
( neutral )

-0.16
( neutral )

0.25
( neutral )

0.30
( neutral )

Skye Bioscience, Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2022
収益:	$0
総利益:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0200

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Skye Bioscience, Inc.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.